Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis

被引:138
作者
Domanski, TL [1 ]
Halpert, JR [1 ]
机构
[1] Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA
关键词
D O I
10.2174/1389200013338612
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Over the past decade, site-directed mutagenesis has become an essential tool in the study of mammalian cytochrome P450 structure-function relationships. Residues affecting substrate specificity, cooperativity, membrane localization, and interactions with redox partners have been identified using a combination of amino-acid sequence alignments, homology modeling, chimeragenesis, and site-directed mutagenesis. As homology modeling and substrate docking technology continue to improve, the ability tv predict more precise functions For specific residues will also advance, making it possible to utilize site-directed mutagenesis to test these predictions. Future studies will employ site-directed mutagenesis to learn more about cytochrome P450 substrate access channels, to define the role of residues that do not lie within substrate recognition sites, to engineer additional soluble forms of microsomal cytochromes P450 for x-ray crystallography, and to engineer more efficient enzymes for drug activation and/or bioremediation.
引用
收藏
页码:117 / 137
页数:21
相关论文
共 155 条
[1]   Targeting of NH2-terminal-processed microsomal protein to mitochondria: A novel pathway for the biogenesis of hepatic mitochondrial P450MT2 [J].
Addya, S ;
Anandatheerthavarada, HK ;
Biswas, G ;
Bhagwat, SV ;
Mullick, J ;
Avadhani, NG .
JOURNAL OF CELL BIOLOGY, 1997, 139 (03) :589-599
[2]   Physiological role of the N-terminal processed P4501A1 targeted to mitochondria in erythromycin metabolism and reversal of erythromycin-mediated inhibition of mitochondrial protein synthesis [J].
Anandatheerthavarada, HK ;
Vijayasarathy, C ;
Bhagwat, SV ;
Biswas, G ;
Mullick, J ;
Avadhani, NG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (10) :6617-6625
[3]   Interaction of adrenodoxin with P4501A1 and its truncated form P450MT2 through different domains: Differential modulation of enzyme activities [J].
Anandatheerthavarada, HK ;
Addya, S ;
Mullick, J ;
Avadhani, NG .
BIOCHEMISTRY, 1998, 37 (04) :1150-1160
[4]  
AOYAMA T, 1989, J BIOL CHEM, V264, P21327
[5]   Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response [J].
Autrup, H .
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2000, 464 (01) :65-76
[6]  
Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3
[7]   Dual targeting property of the N-terminal signal sequence of P4501A1 - Targeting of heterologous proteins to endoplasmic reticulum and mitochondria [J].
Bhagwat, SV ;
Biswas, G ;
Anandatheerthavarada, HK ;
Addya, S ;
Pandak, W ;
Avadhani, NG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (34) :24014-24022
[8]   Nonsubstrate recognition site residues are involved in testosterone hydroxylation by cytochrome P450 CYP 2C11 [J].
Biagini, CP ;
Philpot, RM ;
Célier, CM .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1999, 361 (02) :309-314
[9]   Identification of the binding site on cytochrome P450 2B4 for cytochrome b5 and cytochrome P450 reductase [J].
Bridges, A ;
Gruenke, L ;
Chang, YT ;
Vakser, IA ;
Loew, G ;
Waskell, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (27) :17036-17049
[10]   Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-K-m catalysts of cyclophosphamide and ifosfamide activation [J].
Chang, TKH ;
Yu, L ;
Goldstein, JA ;
Waxman, DJ .
PHARMACOGENETICS, 1997, 7 (03) :211-221